Volume 77, Pages S8-S11 (March 2010)

Slides:

Advertisements

Similar presentations

Ischemic heart disease after renal transplantation

Advertisements

Volume 78, Issue 8, Pages (October 2010)

Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants C.A. Solid,

Michael D. Gautreaux, Barry I. Freedman Kidney International

Renal manifestations in Fabry disease and therapeutic options

Iron status and iron supplementation in peritoneal dialysis patients

Drug use and nephrotoxicity in the intensive care unit

Anemia management in chronic kidney disease

End-stage renal disease in developing countries

Volume 83, Issue 3, Pages (March 2013)

Volume 78, Issue 8, Pages (October 2010)

Subclinical rejection in renal transplants is associated with low serum mannose-binding lectin levels Meritxell Ibernon, Francesc Moreso, Daniel Serón

Continuous renal replacement therapy in the critically ill patient

Volume 80, Issue 10, Pages (November 2011)

Progression of renal failure and hypertensive nephrosclerosis

Volume 77, Issue 1, Pages 6-8 (January 2010)

Need for better diabetes treatment for improved renal outcome

Better nephrology for mice—and man

Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy? Fu L. Luan, Diane E. Steffick,

Volume 77, Issue 1, Pages 5-6 (January 2010)

How to interpret the eGFR in patients with small body surface area

Anemia as a risk factor for chronic kidney disease

Comorbidity and confounding in end-stage renal disease

Volume 74, Issue 3, Pages (August 2008)

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

Volume 87, Issue 2, Pages (February 2015)

Acute myocardial infarction in patients with end-stage renal disease

Prospective randomized study of individual and group psychotherapy versus controls in recipients of renal transplants1 Lyndsay S. Baines, John T. Joseph,

Volume 62, Issue 1, Pages (July 2002)

Volume 75, Issue 11, Pages (June 2009)

Recent experience with high-dose intravenous iron administration

Volume 76, Issue 6, Pages (September 2009)

Bone mass evolution after renal transplantation

Volume 76, Issue 3, Pages (August 2009)

Can we prevent donor-specific antibodies from developing after ABO-incompatible kidney transplantation? Lionel Rostaing, Nassim Kamar Kidney International

Extracorporeal therapy in sepsis: are we there yet?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Tilman B. Drüeke, Ziad A. Massy Kidney International

Volume 85, Issue 1, Pages 3-4 (January 2014)

Counteracting progression of renal disease: A look into the future

Nephrology Crossword: Glomerulonephritis

Volume 80, Issue 3, Pages (August 2011)

Volume 87, Issue 5, Pages (May 2015)

Homocysteine, renal function, and risk of cardiovascular disease

Douglas G Matsell, Colin T White Kidney International

Volume 73, Issue 9, Pages (May 2008)

Long-term survival in renal transplant recipients with graft function

Volume 74, Issue 9, Pages (November 2008)

Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants C.A. Solid,

Organ transplantation goes to the movies

Does equal care give equal outcomes?

Volume 65, Issue 2, Pages (February 2004)

Volume 80, Issue 10, Pages (November 2011)

Volume 83, Issue 4, Pages (April 2013)

Volume 63, Issue 6, Pages (June 2003)

Vikas R. Dharnidharka, Michael E. Seifert Kidney International

Volume 69, Issue 10, Pages (May 2006)

Volume 56, Issue 2, Pages (August 1999)

Is complement a target for therapy in renal disease?

Volume 70, Issue 5, Pages (September 2006)

Ischemic heart disease after renal transplantation

The international realities of live donor kidney transplantation

Abby S. Kazley, Kit N. Simpson, Kenneth D. Chavin, Prabhakar Baliga

Volume 67, Issue 4, Pages (April 2005)

Similar risk profiles for post-transplant renal dysfunction and long-term graft failure: UNOS/OPTN database analysis Nauman Siddiqi, Maureen A. McBride,

The Case ∣ Altered mental status in a transplant patient

Volume 57, Pages S44-S48 (April 2000)

Ronen Levi, Justin Silver Kidney International

Volume 68, Issue 4, Pages (October 2005)

Presentation transcript:

Volume 77, Pages S8-S11 (March 2010) Maintenance immunosuppressive therapy and generic cyclosporine A use in adult renal transplantation: a single center analysis Danielle A. Diarra, Markus Riegersperger, Marcus D. Säemann, Gere Sunder-Plassmann Kidney International Volume 77, Pages S8-S11 (March 2010) DOI: 10.1038/ki.2009.505 Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 1 Use of different classes of immunosuppressants among 1015 kidney transplant recipients. Modified from Säemann and Sunder-Plassmann.1 Kidney International 2010 77, S8-S11DOI: (10.1038/ki.2009.505) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 2 Numbers of kidney transplant recipients using 3, 2, or 1 different classes of immunosuppressant drugs. Modified from Säemann and Sunder-Plassmann.1 Kidney International 2010 77, S8-S11DOI: (10.1038/ki.2009.505) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 3 Serum creatinine (mg/dl) 6 months before and 6 months after conversion of 59 kidney transplant recipients from CsA Neoral to CsA Neoimmun/Equoral (mean±s.d.). Kidney International 2010 77, S8-S11DOI: (10.1038/ki.2009.505) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 4 Estimated GFR (ml/min per 1.73 m2) 6 months before and 6 months after conversion of 59 kidney transplant recipients from CsA Neoral to CsA Neoimmun/Equoral (mean±s.d.). Kidney International 2010 77, S8-S11DOI: (10.1038/ki.2009.505) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 5 CsA daily oral dose (mg/day) 6 months before and 6 months after conversion of 59 kidney transplant recipients from CsA Neoral to CsA Neoimmun/Equoral (mean±s.d.). Kidney International 2010 77, S8-S11DOI: (10.1038/ki.2009.505) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 6 CsA trough level (ng/ml) 6 months before and 6 months after conversion of 59 kidney transplant recipients from CsA Neoral to CsA Neoimmun/Equoral (mean±s.d.). Kidney International 2010 77, S8-S11DOI: (10.1038/ki.2009.505) Copyright © 2010 International Society of Nephrology Terms and Conditions